A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications

Key Inclusion Criteria:

• The participant has a diagnosis of migraine as defined by International HeadacheSociety (IHS) International Classification of Headache Disorders 3rd Edition (ICHD-3) guidelines with a history of migraine of at least 12 months prior to theScreening Visit.

• The participant has ≥8 migraine days per month for each month within the past 3months prior to the Screening Visit.

• The participant has documented evidence of recent inadequate response to either oneanti-CGRP monoclonal antibody (mAb) (other than eptinezumab) or one gepant,indicated and used for migraine prevention.

Key Exclusion Criteria:

• The participant has taken more than 10 tablets of ubrogepant or more than 8 tabletsof rimegepant per month as an acute migraine medication in the 1 month prior to thescreening visit and during the 4-week baseline period.

• The participant has previously had an inadequate response to more than oneCGRP-targeting therapy (anti-CGRP mAb or gepants), indicated for migraineprevention.

• The participant has a history of cancer, other than basal cell or stage 1 squamouscell carcinoma of the skin or adequately treated cervical intraepithelial neoplasia,that has not been in remission for >5 years prior to the first dose of eptinezumab.Male participants with abnormal prostate-specific antigen levels according tonational/local guideline may be enrolled in the trial provided they have beenfollowed up, have been asymptomatic, and have had no treatment for prostate cancer.Participants under surveillance for a low and stable level of M-component areallowed.

• The participant has previously been treated with eptinezumab.

Other protocol-defined inclusion and exclusion criteria apply.